ArticleOncoimmunology
A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies.
Dedong Cao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
52 papers cite it
pooled ittrialcites it